Other languages NRx Pharmaceuticals, Inc.

Equities

BRPA

US6294442099

Real-time Estimate Cboe BZX Other stock markets 10:08:27 29/04/2024 pm IST			5-day change	1st Jan Change
3.54 ^USD	0.00%		+21.66%	-20.66%

18/04	NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq	MT
18/04	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches	18/04
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics	17/04
NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)	15/04
NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression	08/04
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03
NRx Pharmaceuticals, Inc., Conversio Health, LLC and Nephron Pharmaceuticals Corporation Complete Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)	11/03
NRX Pharmaceuticals Announces Last Patient, Last Visit in Its Phase 2B/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression	04/03
NRx Pharmaceuticals, Inc. Announces Completion of Enrollment of Its Phase 2b/3 Trial of NRx-101 in Suicidal Treatment Resistant Bipolar Depression	22/01
NRx Pharmaceuticals, Inc. Announces FDA Qualified Infectious Disease Product and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis	16/01
NRx Pharmaceuticals Says It Reached Nasdaq Listing Compliance	03/01
Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors	27/12
NRx Pharmaceuticals, Inc. Announces FDA Clearance of its Investigational New Drug Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections	18/12
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11
NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression	06/11
NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and Depression	31/23/31
NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain	26/23/26
NRx Pharmaceuticals Announces Strategic Acceleration of its Plans to Develop Commercial Form of NRX-100 (intravenous ketamine) to Treat Acute Depression and Suicidality	12/23/12
NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug Application for NRX-101 to Treat Chronic Pain	02/23/02
NRX Pharmaceuticals Signs Data Sharing Agreement to Support FDA Submission on Suicidal Bipolar Depression Therapy	15/23/15
NRx Pharmaceuticals, Inc. Announces Data Sharing Agreement Demonstrating Efficacy and Safety of Intravenous Ketamine for Treatment of Suicidal Bipolar Depression	15/23/15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages NRx Pharmaceuticals, Inc.

Equities

BRPA

US6294442099

Other languages

Filters